NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

This is the combo study that the patent pertains to. The company has also built and secured a comprehensive worldwide patent portfolio.

Aside from the well-publicized P3, there is another clinical study for murcidencel + pembrolizumab specifically for rGBM that has reached its midpoint with interim survival data. This study does not involve any chemo or radiation. OS has not been reached yet because patients are alive. This trial is using an internal placebo control group who are all receiving murcidencel—only Keytruda in combo is being investigated.

https://clinicaltrials.gov/ct2/show/NCT04201873



Murcidencel (DCVax-L) is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus DCVax in combo at UCLA, skip to minute 45:40